ARTICLE BY BIO X CELL
Translational Continuity: Why Drug Programs Fail Early
In a recent blog post titled “Translational Continuity: Why Drug Programs Fail Early,” Bio X Cell introduced insights into why over 90% of drug candidates fail during clinical trials. A primary culprit is that traditional animal models frequently fail to accurately mimic human biology, toxicity, and drug metabolism.
All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.
ABOUT BIO X CELL
Empowering scientists with precision in vivo antibodies
Researchers must have access to the right products, services, and support for successful scientific breakthroughs. However, sourcing reliable antibodies can be complex, costly, and fraught with delays. Additionally, poor product quality can compromise data integrity, contribute to reproducibility challenges, and hinder the progress of your program.
For nearly 30 years, Bio X Cell has been committed to researchers’ success, setting the standard for antibody performance, quality, and reliability in translational and preclinical research.
- Global leader of in vivo ready functional antibody solutions
- Scalable production from milligrams to grams
- Exceptional quality & purity
- Custom services for catalog modifications or your own antibodies
All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.